Carfilzomib-related acute kidney injury

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 9, 2013, Pages 604-605

  Jhaveri, Kenar D ^a,d   Chidella, Shailaja ^a,d   Varghese, Jeny ^d   Mailloux, Lionel ^a,d   Devoe, Craig ^b,c,d  

^a Division of Kidney Diseases and Hypertension   (United States)

^b Department of Medicine   (United States)

^c North Shore LIJ Cancer Institute   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARFILZOMIB; CREATININE; DEXAMETHASONE; IMMUNOGLOBULIN KAPPA CHAIN;

ACUTE KIDNEY FAILURE; AGED; CASE REPORT; FEVER; GLUCOSURIA; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; NOTE; URINALYSIS;

ACUTE KIDNEY INJURY; AGED; HUMANS; MALE; MULTIPLE MYELOMA; OLIGOPEPTIDES;

EID: 84884370397     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Fostier K, De Becker A, Schots R. Carflzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ter. 2012;5:237-244.
2. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carflzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-2825.
3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ter. 1981;30(2):239-245.
4. US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEfects/default.htm. Updated September 10, 2012. Accessed January 10, 2013.